Photo credits
Why Selegiline Still Matters
Monoamine oxidase inhibitors are the most effective antidepressants almost no one prescribes. In treatment-resistant depression they deliver roughly a 50% response rate in patients who have already failed two or more prior trials, and in atypical depression (the presentation with mood reactivity, hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity) they outperform tricyclics. Yet only about 2% of psychiatrists prescribe MAOIs with any regularity. The reasons are cultural, not clinical: fear of hypertensive crisis, fear of serotonin syndrome, the burden of a tyramine-restricted diet, and a reputation forged in an era when the dietary lists were absurdly long and the pharmacology poorly understood.
Selegiline exists to solve that problem. The transdermal patch (Emsam) is the one MAOI you can start on a patient without imposing dietary restrictions, at least at its lowest, fully therapeutic dose. It is FDA-approved for major depressive disorder and delivered through the skin, and it is engineered around one pharmacologic trick: by bypassing the gut and liver, it floods the brain with MAO inhibition while leaving intestinal MAO-A largely intact to keep destroying dietary tyramine. The result is an MAOI with the mechanism of the old drugs and a fraction of their baggage. The rest of this guide is about using that advantage without being lulled by it.
The 6 mg patch is a low-hassle antidepressant: no diet at a steady 6 mg (the diet continues for 2 weeks after a reduction from 9 or 12 mg), a placebo-like side-effect profile, and none of the metabolic and sexual burden that drives patients off the older MAOIs. But once you go to 9 or 12 mg, you are prescribing a full, non-selective MAOI, and every classic MAOI rule applies again.
If you understand where that line sits and respect it, Emsam is one of the most useful and best-tolerated tools for depression that has failed the usual agents.
One caveat applies to everything below. Emsam's efficacy data come almost entirely from placebo-controlled trials in general major depression. It has not been studied in the atypical or treatment-resistant populations where oral MAOIs earn their keep, and the doses that would treat true TRD (an oral-equivalent well above the patch's ceiling) can't be reached with the patch anyway. So Emsam is best understood as the accessible on-ramp to MAOI therapy. For the truly refractory patient, it is not a replacement for phenelzine or tranylcypromine.
How to Use Selegiline With Confidence
MAOIs sit untouched at the bottom of the algorithm because clinicians are afraid of them, not because anyone weighed the evidence and found them wanting. The fears are specific: the phone call at 2 a.m. after a patient ate the wrong cheese, serotonin syndrome from a co-prescription you didn't catch, a diet that seems impossible and interactions that look like a minefield. If that's you, this section is for you, and selegiline is the drug that makes the fear tractable.
Why MAOIs Feel Dangerous, and the Fix
MAOIs feel dangerous because two of their interactions are potentially catastrophic: hypertensive crisis (tyramine or sympathomimetics driving blood pressure to stroke-range levels) and serotonin syndrome (adding a serotonergic drug to an MAOI). Both risks are real, and both are entirely preventable with a system.
Handle MAOI safety with a protocol instead of relying on vigilance: a short checklist you run once at the start and a small set of rules the patient carries with them.
Selegiline is the ideal entry point because at a steady 6 mg patch the single scariest interaction, dietary tyramine, is largely off the table: the label says a modified diet is not required at 6 mg (the diet does continue for 2 weeks after a reduction from 9 or 12 mg). The pharmacology supports that (more on the mechanism below). You are left managing only the serotonergic and sympathomimetic interactions, and those are governed by your prescription pad rather than by what the patient orders for dinner. That leaves you far less to control.
The Systematic Approach
Build a one-page interaction and diet sheet, and give it to the patient in writing. This is the single highest-yield thing you can do. It should list, in plain language:
- The drugs that must never be combined (serotonergic antidepressants, dextromethorphan, meperidine, decongestants; more below)
- The instruction to tell every prescriber, dentist, and pharmacist that they are on an MAOI before any new medication
- For 9–12 mg patients, and for 2 weeks after a reduction to 6 mg: the tyramine diet (aged cheeses, cured/aged meats, tap/draft beer, fava beans, sauerkraut, marmite, soy sauce in quantity)
- The warning sign of hypertensive crisis: a sudden, severe, "splitting" headache
- Your phone number and what to do in an emergency
Run the washout math before you write the prescription. The most common way to get into trouble is starting an MAOI too soon after a serotonergic drug. Before Emsam:
- Taper and stop the prior antidepressant. The label asks for 4 to 5 half-lives, about a week for most agents; waiting 2 weeks is the conventional safer margin before the first patch.
- Fluoxetine is the trap: wait 5 weeks, because of its and norfluoxetine's long half-life.
- Bridge the gap with a benzodiazepine if the patient is struggling.
Establish a blood-pressure baseline and teach home monitoring. Day to day, MAOIs classically cause orthostatic hypotension, not hypertension; the crisis is the exception. Get a seated and standing BP at baseline, and teach the patient to check at home (sitting, then standing after 2–3 minutes, recording both). This tells you whether to slow your titration.
Give the patient a written emergency plan rather than a pill to carry. Teach the crisis headache, have them check their BP if they can, and send them to an emergency department instead of treating it at home. The patient-carried immediate-release nifedipine "amulet" is no longer advised: chewed or sublingual nifedipine can drop pressure uncontrollably and has caused ischemic events. A plan the patient can recite does the same reassuring work without that risk.
Choose the right dose for the right goal. If the patient is diet-averse, interaction-anxious, or you simply want the cleanest possible MAOI trial, stay at 6 mg and keep the dietary freedom. If you need more antidepressant effect and the patient is reliable, you can go to 9 or 12 mg, but you are now running a full MAOI and must implement the diet.
Addressing the Specific Fears
At a steady 6 mg, the label says a modified diet is not required, based on its tyramine challenge studies (the diet does continue for 2 weeks after a reduction from 9 or 12 mg). What remains is sympathomimetics (decongestants, stimulants, cocaine), and those are controlled by education and your prescribing. Real hypertensive events in careful practice are rare; one veteran MAOI prescriber logged a single bad event in over 30 years, and it required a patient massively overdosing on Sudafed.
This is the more important risk with selegiline, and it is 100% a prescribing-side problem. Don't co-prescribe serotonergic agents (SSRIs, SNRIs, clomipramine, meperidine, dextromethorphan, tramadol, triptans without caution), and respect washouts. If you control the med list, you control this risk.
For a steady 6 mg, there is no diet (it continues for 2 weeks after a reduction from 9 or 12 mg). For 9–12 mg, the label's Table 5 applies: aged cheeses, air-dried, aged or fermented meats and sausages, spoiled meat, fish or liver, fava bean pods, tap beer and unpasteurized beer, concentrated yeast extracts such as Marmite, sauerkraut and most soybean products; mozzarella, ricotta, cottage cheese, yogurt, processed cheeses and chain-restaurant pizza made with low-tyramine cheeses are acceptable.
The 6 mg patch is arguably the most forgiving MAOI for a marginally reliable patient, because at a steady 6 mg a dietary slip is far less of a concern (after a reduction from 9 or 12 mg, the diet still applies for 2 weeks). The patch also removes the "did I take my pill" problem: you can see it on their skin.
Selegiline is the MAOI designed to remove the fear. The 6 mg patch removes the diet requirement (after the 2-week window that follows a reduction from 9 or 12 mg), the metabolic and sexual side effects, and much of the orthostasis, leaving a well-tolerated antidepressant whose only real cautions live on your prescription pad. Learn the short list of drugs to avoid, run the washout, hand the patient a one-page sheet, and you can offer MAOI-class benefit to patients who would never tolerate, or comply with, the older agents.
Part 1: Indications
FDA-Approved Use
- Major depressive disorder: the transdermal patch (Emsam) only.
Oral selegiline (Eldepryl) is FDA-approved for Parkinson's disease as an adjunct, not for depression; its use for depression at 30–60 mg/day is off-label and never formally approved for that purpose in the US.
The Evidence-Based Clinical Picture
Major depression (patch)
All Emsam registration trials were placebo-controlled; there are no head-to-head trials against other antidepressants. Efficacy appears modest and broadly comparable to other antidepressants. What the patch sells on is tolerability and, at 6 mg, the elimination of the tyramine diet.
Atypical and treatment-resistant depression
These are the MAOI class's true sweet spots, with an important asterisk for the patch:
- Atypical depression (mood reactivity, hypersomnia, hyperphagia, leaden paralysis, rejection sensitivity): MAOIs beat tricyclics; many clinicians favor them here.
- Treatment-resistant depression: MAOIs are a Stage-4 option in standard TRD algorithms, with ~50% response after ≥2 failed TCA trials.
- The asterisk: the Emsam patch has not been studied in either population, and the oral-equivalent dose likely needed for TRD (well above what the patch delivers) can't be reached transdermally. For real TRD or atypical depression in a diet-capable patient, an oral MAOI (phenelzine, tranylcypromine) is the better-evidenced choice.
Off-label MAOI-class uses (based on oral MAOIs, not specifically the patch)
Social anxiety disorder (phenelzine has a large effect size across RCTs), panic disorder (especially with comorbid social anxiety), dysthymia, and pilot-level data in PTSD and bulimia. The patch has limited social-anxiety data.
Geriatric depression
Oral selegiline has treated depression successfully in treatment-refractory geriatric patients. That is useful to know, given how few options remain in that group.
Who Is Selegiline Best For?
- A patient with depression that has failed better-marketed first-line agents, who is MAOI-curious but diet- or interaction-phobic (the 6 mg patch's core niche)
- A patient who can't tolerate the metabolic, sexual, or sedating burden of older MAOIs or of SSRIs/SNRIs
- A patient in whom adherence is uncertain and a visible, once-daily patch helps
- A patient who needs an MAOI trial but whose reliability around a diet you don't fully trust
Who Is a Poor Candidate?
- A patient with true treatment-resistant or clearly atypical depression who needs an adequately dosed MAOI: reach for an oral agent
- A patient on multiple serotonergic agents that can't be stopped
- A patient with pheochromocytoma (absolute contraindication) or uncontrolled hypertension
- A patient who cannot or will not observe the diet if you intend to use 9–12 mg
- A patient with significant cardiovascular disease prone to orthostatic events
Match the formulation to the goal. If your goal is "give an MAOI-averse patient the easiest possible MAOI," Emsam 6 mg is purpose-built. If your goal is "rescue a truly refractory depression," Emsam is the wrong tool: its ceiling is too low and its TRD evidence is absent. Don't let the patch's convenience talk you into using it for a job it can't do.
Part 2: Before You Start: Workup and Candidacy
Selegiline requires no routine laboratory monitoring: no drug levels, no blood counts, no ECG (unlike lithium or TCAs). The workup is clinical, and it centers on hemodynamics, the medication list, and patient education.
Baseline Assessment
| Assessment | Why |
|---|---|
| Seated and standing BP + HR | Orthostatic hypotension is the most common problematic MAOI effect; this is your baseline to titrate against |
| Full medication reconciliation | The whole safety of an MAOI lives here: hunt for serotonergic agents, decongestants, tramadol, dextromethorphan, meperidine, triptans, stimulants |
| Washout planning | Calculate the gap from any prior antidepressant (see below) before writing the script |
| Cardiovascular history | CVD raises the stakes of both orthostasis and any hypertensive event |
| Substance-use history | Stimulant, cocaine, and heavy-alcohol use are dangerous with any MAOI |
| Diet and reliability assessment | Determines whether you can safely push to 9–12 mg |
| hCG | In any patient of childbearing potential (limited pregnancy safety data) |
The Washout Rules (Get This Right Before the First Patch)
- From most antidepressants: the label asks for 4 to 5 half-lives, about a week for most agents; ≥2 weeks is the conventional safer margin.
- From fluoxetine: wait 5 weeks (long half-life of fluoxetine and norfluoxetine).
- From vortioxetine: at least 21 days after the last dose (Trintellix label).
- Coming off selegiline before starting a new serotonergic drug: step the dose down rather than stopping abruptly, then wait 2 weeks after the last patch before the new agent (irreversible MAO inhibition means the enzyme must regenerate).
- Bridge the drug-free gap with a benzodiazepine if symptoms are hard to tolerate.
Who Should Not Start
- Pheochromocytoma (absolute)
- Concurrent sympathomimetics that can't be stopped
- Concurrent serotonergic agents that can't be stopped or washed out
- Uncontrolled hypertension; significant cardiovascular disease (relative)
- Inability to observe the diet, if 9–12 mg is intended
Part 3: How to Start and Dose
Older adults (65 and older)FDA label6 mg per 24 hours once daily, the recommended dose for elderly patients (65 years and older).In practice6 mg per 24 hours, with no routine escalation: older patients are the most susceptible to orthostatic hypotension and falls.
How and when to applyFDA labelShould be applied once every 24 hours to dry, intact skin: upper torso (below the neck and above the waist), upper thigh or outer upper arm.In practiceReplace the patch every 24 hours at a consistent time. Rotate the site daily; avoid the same spot on consecutive days.
Stopping and dose reductionFDA labelTyramine-rich foods should be avoided for 2 weeks after a dose reduction to 6 mg per 24 hours, or after stopping 9 or 12 mg per 24 hours.In practiceStep the dose down rather than stopping abruptly. Keep drug and diet restrictions about 2 weeks after the last patch.
Children and adolescents1 row
Formulation
- Emsam transdermal patch (the psychiatric formulation): three strengths: 6 mg/24 h (20 cm²), 9 mg/24 h (30 cm²), and 12 mg/24 h (40 cm²), containing 20, 30, and 40 mg of selegiline respectively (1 mg/cm²; roughly 0.3 mg/cm² delivered over 24 h, with ~25–30% of the patch content absorbed systemically). Brand-only, no generic. Applied once daily to intact, dry skin on the upper torso (below the neck and above the waist), upper thigh, or outer upper arm; rotate the site daily and avoid reapplying to the same spot on consecutive days.
- Oral selegiline (a Parkinson's drug, not an antidepressant at its labeled doses): Eldepryl 5 mg capsules (generic also as 5 mg tablets) and Zelapar 1.25 mg orally disintegrating tablets. Their FDA-labeled dosing treats Parkinson's disease (see Dosing by Indication) and is MAO-B selective, and therefore diet-free, only at ≤10 mg/day, which is subtherapeutic for depression. Treating depression by mouth requires roughly 30–60 mg/day, at which point selegiline is non-selective and requires the full MAOI diet. The patch supersedes oral selegiline for depression.
Dosing by Indication
- Major depressive disorder, Emsam patch (FDA-approved): the recommended starting dose and target dose is 6 mg/24 h. Efficacy has been demonstrated across 6–12 mg/24 h; increase only if the response at 6 mg/24 h is inadequate.
- MAOI-class off-label uses (atypical and treatment-resistant depression, social anxiety, panic) rest on data from the oral MAOIs, not the patch. If you use the patch for these, dose it as above and recognize the efficacy evidence is extrapolated.
- Parkinson's disease, oral selegiline (context only, not a psychiatric regimen): Eldepryl 10 mg/day, given as 5 mg at breakfast and 5 mg at lunch (do not exceed 10 mg/day); Zelapar ODT 1.25 mg once daily for 6 weeks, then up to a maximum of 2.5 mg/day. These are MAO-B-selective antiparkinsonian doses, not antidepressant dosing.
The Dose-Diet Threshold
The dose at which the diet returns is the most important concept in selegiline prescribing.
| Patch dose | Dietary restriction? | Pharmacologic status |
|---|---|---|
| 6 mg/24 h | No | Therapeutic; gut MAO-A preserved to clear tyramine. After a reduction from 9 or 12 mg, the diet continues for 2 weeks |
| 9 mg/24 h | Yes (standard MAOI diet) | Non-selective inhibition; tyramine risk returns |
| 12 mg/24 h | Yes (standard MAOI diet) | Non-selective inhibition; tyramine risk returns |
6 mg = no diet (after the 2-week window that follows a reduction from 9 or 12 mg). 9 mg and 12 mg = the Table 5 diet is required.
The label requires the Table 5 diet from the first day of 9 or 12 mg, and for 2 weeks after a reduction to 6 mg or after stopping, because a tyramine-induced hypertensive crisis can be life-threatening.
Starting Dose and Titration
- Start at 6 mg/24 h. For most patients this is both the starting and the maintenance dose.
- Titrate slowly, no faster than every 2 weeks, in 3 mg increments, to a maximum of 12 mg/24 h, guided by response and tolerability (chiefly orthostasis).
- Going slow protects against orthostatic hypotension, the main dose-limiting effect.
- Serotonergic and sympathomimetic precautions apply at every dose, including 6 mg. The 6 mg exemption is dietary only; it does not exempt you from the drug-interaction rules.
Target Dose
- For most patients, 6 mg/24 h is the target, not merely the start. It is the only dose that is both antidepressant-effective and free of the tyramine diet, and it is the recommended dose in the elderly.
- The maximum is 12 mg/24 h. Escalate to 9 or 12 mg/24 h only for inadequate response at 6 mg/24 h, in 3 mg/24 h steps no sooner than every 2 weeks.
- Every step above 6 mg/24 h re-imposes the standard MAOI tyramine diet. At 9 or 12 mg/24 h, tyramine-rich foods must be avoided from the first day of the higher dose and, per the label, for 2 weeks after any dose reduction back down. Going above 6 mg/24 h therefore means taking on dietary management, so make that choice deliberately.
- Unlike the oral MAOIs, there is no "push to ~1 mg/kg" imperative here: higher patch doses buy uncertain extra efficacy at the cost of the diet, so 6 mg/24 h is where most patients should stay unless the clinical need is clear.
Dose Equivalence (for Context)
- Emsam 6 mg patch ≈ 20 mg oral selegiline (the transdermal route is more efficient because it bypasses first-pass hepatic metabolism).
- That first-pass bypass is why the patch achieves brain MAO inhibition at a dose low enough to spare gut MAO-A.
Timing
- Apply once daily; a consistent time helps adherence.
- Each patch is worn for 24 hours and then replaced.
Dose Adjustments and Special Populations
- Geriatric (≥ 65): the recommended dose is 6 mg/24 h; older patients are the most susceptible to orthostatic hypotension and falls, so there is no routine escalation.
- Renal impairment: no dosage adjustment is required for mild, moderate, or severe impairment; Emsam has not been studied in end-stage renal disease. Monitor for orthostasis regardless.
- Hepatic impairment: no dosage adjustment is required for mild or moderate impairment; Emsam has not been studied in severe hepatic impairment.
- Pediatric: Emsam is contraindicated under age 12 and not recommended for ages 12–17 (efficacy was not established in adolescents); the antidepressant suicidality warning for children, adolescents, and young adults applies.
- Pregnancy / lactation: no defined dose adjustment; the question is whether to use it at all. Data are limited; weigh untreated depression against sparse fetal- and infant-safety data case by case (see Part 8).
Stopping and Switching
- Discontinuation: the Emsam label gives no taper schedule and describes no withdrawal syndrome. The Parnate and Nardil labels do report withdrawal effects after abrupt MAOI cessation (delirium with tranylcypromine; agitation, psychosis and convulsions with phenelzine), so stepping the dose down rather than stopping abruptly is the cautious course here too, by analogy to those labels. Because selegiline inhibits MAO irreversibly, the drug interaction and (at 9–12 mg/24 h) dietary restrictions must stay in force for ~2 weeks after the last patch while new enzyme regenerates.
- Switching onto Emsam from another antidepressant: let the prior drug wash out first. The Emsam label specifies a minimum of 4–5 half-lives (about 1 week for most agents) between stopping the previous drug and starting Emsam; many clinicians use the conventional ~2-week MAOI washout to be safe. After fluoxetine, wait at least 5 weeks because of its long-lived active metabolite.
- Switching off Emsam to a serotonergic drug or another MAOI: allow at least 2 weeks after the last patch before starting the new agent, so MAO can regenerate (full detail in Parts 2 and 9).
Part 4: Monitoring
Selegiline's monitoring is light. There are no required drug levels, blood counts, or ECGs. You watch hemodynamics, tolerability, adherence to the interaction/diet rules, and the patch site.
| Timepoint | What to check |
|---|---|
| Baseline | Seated + standing BP/HR; full med reconciliation; diet/interaction teaching |
| First 2–4 weeks | Frequent contact (e.g., weekly) during titration: BP, orthostatic symptoms, insomnia, patch-site skin, response |
| Ongoing (each visit) | BP; reinforce diet/interaction counseling; screen for any new prescriptions or OTC use; assess mood response |
| Home monitoring | Teach the patient to check sitting-then-standing BP (2–3 min apart) and record BP + HR |
What to Act On
- Symptomatic orthostasis / falls risk: slow the titration, reduce the dose, increase fluids, consider support stockings; fludrocortisone in refractory cases.
- Patch-site irritation: rotate the site daily; topical hydrocortisone (let it dry before applying the patch).
- Any sudden severe headache: treat as a possible hypertensive emergency; check BP, and if markedly elevated, activate the emergency plan.
- A new prescription from another provider: re-screen the entire list for serotonergic/sympathomimetic conflicts every single time.
For an MAOI, the most important "monitoring" is the medication list, not a lab: re-check it at every encounter and any time another clinician gets involved. Make "any new meds, from anyone?" a standing question at every visit. That habit prevents the two interactions that actually hurt people.
Part 5: Side Effects and How to Manage Them
Selegiline reverses the usual MAOI story: at 6 mg, the side-effect profile is nearly placebo-like except for insomnia and patch-site irritation. Tolerability is the patch's whole clinical identity, with markedly less weight gain, fatigue, sexual dysfunction, and orthostasis than phenelzine or tranylcypromine.
Skin and Patch-Site Irritation (the Most Common Patch-Specific Effect)
Management:
- Rotate the application site every day.
- Apply topical hydrocortisone to the site and let it dry fully before applying the patch.
- Ensure skin is clean, dry, and intact.
Insomnia (the Most Common Non-Skin Effect)
Management:
- Reassess caffeine and sleep hygiene.
Orthostatic Hypotension
Less problematic with the patch than with oral MAOIs, but still the main dose-limiting hemodynamic effect (a paradoxical reduction in sympathetic outflow can occur with any MAOI).
Management:
- Titrate slowly (the primary prevention).
- Increase fluid intake (aim for good hydration; ~8 glasses of water/day).
- Support/compression stockings.
- Reduce or adjust concurrent antihypertensives.
- Dose reduction if needed.
- Fludrocortisone for severe, refractory orthostasis.
- Teach home sitting-to-standing BP checks to guide titration.
Reduced Burdens vs. Older MAOIs
- Weight gain: minimal (a major advantage over phenelzine).
- Sexual dysfunction: minimal.
- Fatigue/sedation: minimal.
These favorable comparisons are one of the strongest reasons to consider Emsam in a patient who needs MAOI-class benefit but was miserable on, or refused, an older agent.
When a patient tells you they "can't tolerate antidepressants" because of weight gain and sexual side effects, the 6 mg patch is worth naming specifically. On exactly those two domains its profile is close to placebo, which you can rarely say about an effective antidepressant.
Part 6: Overdose, Toxicity, and Boxed Warnings
Selegiline carries the antidepressant class boxed warning for suicidality, and it shares the two dangerous emergencies of the whole MAOI class: hypertensive crisis and serotonin syndrome. The patch at 6 mg substantially lowers the hypertensive-crisis risk by removing dietary tyramine as a trigger, but the serotonergic risk is undiminished at any dose.
- Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies; monitor all antidepressant-treated patients closely for clinical worsening and for emergence of suicidal thoughts and behaviors. The same box states that Emsam is contraindicated in patients less than 12 years of age because of an increased risk of hypertensive crisis.
The MAOI Class Safety Warnings (Not Boxed Warnings)
- Serotonin syndrome (contraindication and warning). With serotonergic agents; such co-administration is contraindicated.
- Hypertensive crisis (warning/precaution; carbamazepine and use under age 12 are contraindicated because of it). With tyramine-rich foods (diet required at 9 and 12 mg) and with sympathomimetic amines, amphetamines or buspirone (the label says to monitor blood pressure, at any dose).
- Withdrawal after abrupt cessation (class caution). The Emsam label describes none. The caution rests on the Parnate label (withdrawal effects, including delirium) and the Nardil label (an uncommon withdrawal syndrome that can include psychosis and convulsions), hence step the dose down rather than stop abruptly (see Part 9).
Hypertensive Crisis: Recognition and Management
Warning sign to teach: a sudden, severe, occipital "splitting" headache; possibly palpitations, neck stiffness, sweating, nausea. If the patient can, check BP: sustained readings of 180 systolic or 110 diastolic and above define hypertensive urgency, and signs of end-organ damage make it an emergency.
Acute treatment:
- Do not give or prescribe immediate-release nifedipine for the patient to chew. It can drop blood pressure faster than the brain and heart tolerate, which can cause stroke or sudden permanent blindness (Gillman 2020). The 2022 Prescriber's Guide to Classic MAO Inhibitors (Van den Eynde et al.) calls sublingual nifedipine strongly contraindicated, and the old carry-it-with-you rescue is retired.
- The label's instruction: discontinue Emsam immediately, institute therapy to lower blood pressure immediately, manage fever by external cooling, and monitor closely until symptoms stabilize. A hypertensive crisis can be life-threatening.
- Send the patient for emergency evaluation when readings stay at or above 180 systolic or 110 diastolic, or there are signs of end-organ damage. Phentolamine is the traditional agent, and the 2022 guide suggests an infusion because its half-life is only about 19 minutes and it can be titrated. The emergency physician treats with the short duration of the reaction in mind.
- The older suggestion to prescribe labetalol capsules for home use cannot be supported (Van den Eynde et al. 2022).
Serotonin Syndrome: Recognition
- Triad of mental-status change, autonomic instability, and neuromuscular hyperactivity (clonus, hyperreflexia, tremor, hyperthermia, agitation).
- Serotonin syndrome is more common and more severe with MAOIs than with most other antidepressant combinations, which is why the washout and interaction rules are non-negotiable.
Management is emergent: stop the offending agents, provide supportive care and cooling, use benzodiazepines, and give cyproheptadine in significant cases. The ED manages the severe end.
Part 7: Drug Interactions
With selegiline, safety rests on the interaction list. Get it right and the medication is safe; get it wrong and you risk the two emergencies above. The serotonergic and sympathomimetic rules apply at 6 mg just as they do at 12 mg; only the dietary tyramine restriction is dose-dependent.
1. Serotonergic Agents: Serotonin Syndrome Risk
Absolutely contraindicated / avoid:
- SSRIs and SNRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, etc.)
- Clomipramine and imipramine: both named on the label; clomipramine is the most serotonergic TCA.
- Meperidine: major risk; a classic fatal interaction.
- Dextromethorphan: hidden in OTC cough/cold products.
- Tramadol, methadone, pentazocine, and propoxyphene, all contraindicated on the label; also St. John's wort and L-tryptophan.
- Ziprasidone: its own label contraindicates it in patients taking an MAOI, or within 14 days of stopping one, because of serotonin syndrome risk.
- Carbamazepine: contraindicated on the label, which is a change from how it is often taught. It roughly doubles systemic selegiline exposure and with it the risk of a hypertensive crisis, at any patch dose.
Use only with caution:
- Triptans (theoretical serotonergic additive effect, use with caution)
- Buspirone (theoretical additive risk; limited real-world events)
2. Sympathomimetics: Hypertensive-Crisis Risk (All Doses)
- OTC decongestants: pseudoephedrine, phenylephrine (a major cause of avoidable events; the label says to monitor blood pressure if sympathomimetics such as pseudoephedrine are used with Emsam, and the safest counsel remains avoidance/caution).
- Stimulants of abuse: cocaine, amphetamines, MDMA, all can precipitate a hypertensive crisis.
- Excessive alcohol: raises hypertensive risk.
- Prescribed psychostimulants (methylphenidate, dextroamphetamine): historically used cautiously as MAOI augmentation by experts without crises, but this is a specialist maneuver, not routine.
3. Dietary Tyramine: Dose-Dependent
Only the tyramine restriction is dose-dependent; the serotonergic and sympathomimetic rules above apply at every dose. At a steady 6 mg, the label says a modified diet is not required (the diet continues for 2 weeks after a reduction from 9 or 12 mg). At 9–12 mg, the label's Table 5 diet applies.
- Aged cheeses
- Cured, aged, or spoiled meats
- Draft/tap beer
- Fava bean pods
- Sauerkraut
- Marmite / concentrated yeast extracts
- Most soybean products (soy sauce, tofu)
- Mozzarella, ricotta, cottage cheese, yogurt and processed cheeses; chain-restaurant pizza made with low-tyramine cheeses (label Table 5)
4. Anesthesia and Surgery
Flag the MAOI to any surgeon or anesthesiologist well in advance; avoid meperidine and certain vasopressors perioperatively; coordinate on timing.
Agents That CAN Be Combined (with Appropriate Care)
- Bupropion (non-serotonergic)
- Mirtazapine, trazodone, trimipramine, desipramine, and doxepin as an oral hypnotic/antidepressant: reportedly usable in expert hands (note: trazodone and Silenor/doxepin appear on formal contraindication lists yet have real-world safe-use experience; proceed only with caution and expertise). Doxepin/Silenor is often listed as not safe, so do not assume otherwise.
- Benzodiazepines: safe (useful for washout bridging and for adjunctive sleep/anxiety)
- Augmentation with the best evidence: lithium. Also second-generation antipsychotics (except ziprasidone), thyroid (T3), and, cautiously, psychostimulants.
The two questions that prevent almost every MAOI disaster are: "Are you taking anything serotonergic?" and "Are you taking anything for a cold, congestion, or as a stimulant?" Ask both at every visit, ask about OTC products and supplements explicitly, and make sure every other prescriber knows the patient is on an MAOI.
Part 8: Special Populations
Pregnancy
- Limited safety data: MAOIs are an older class and poorly studied in pregnancy. Generally avoided when safer, better-characterized alternatives exist.
- A careful risk/benefit discussion is essential; weigh the danger of untreated depression against sparse fetal-safety data.
Lactation
- Transfer into breast milk is not well characterized. Caution is warranted; individualize the risk/benefit decision in coordination with pediatrics.
Elderly
- Orthostatic hypotension is the dominant concern: falls, ischemia, confusion. Start low, titrate slowly, monitor BP closely.
- The patch's lower orthostatic burden vs. oral MAOIs is a point in its favor here, and oral selegiline has a track record in refractory geriatric depression.
Renal Impairment
- Per the EMSAM label, no dosage adjustment is required for mild, moderate, or severe renal impairment; it has not been studied in end-stage renal disease. Monitor for orthostasis regardless.
Hepatic Impairment
- Per the EMSAM label, no dosage adjustment is required for mild or moderate hepatic impairment; it has not been studied in severe hepatic impairment. (Transdermal delivery bypasses first-pass metabolism, which is part of why hepatic exposure differs from oral selegiline.)
Children and Adolescents
- Not recommended: limited safety/efficacy data, and dietary/interaction compliance is a particular concern in this group. The antidepressant suicidality class warning also applies.
Part 9: Discontinuation
Selegiline is an irreversible MAOI: stopping the drug doesn't restore MAO activity until new enzyme is synthesized, which takes roughly 2 weeks. This shapes both how you stop it and how long the restrictions persist afterward.
- Step the dose down rather than stopping abruptly. The Emsam label gives no schedule and describes no withdrawal syndrome; the caution comes from the Parnate and Nardil labels, which report withdrawal effects after abrupt MAOI cessation.
- After the last patch, keep the drug and dietary restrictions in place for another ~2 weeks: the enzyme (and thus the interaction risk) persists after the drug is gone.
- Do not start a new serotonergic antidepressant until that full ~2-week enzyme-recovery window has passed (a fresh washout in the reverse direction).
- Maintenance is supported by the label's continuation trial: responders kept on 6 mg/24 h had a significantly longer time to relapse than those switched to placebo. Reassess the plan as you would with any antidepressant.
The dangerous window with an irreversible MAOI is the two weeks after you stop. Patients (and covering clinicians) often assume that once the patch is off, the rules are off. They are not. Write the stop date and the "restrictions continue until [date + 2 weeks]" date on the same instruction sheet.
Part 10: Selegiline vs. the Alternatives
vs. Oral MAOIs (Phenelzine, Tranylcypromine, Isocarboxazid)
Emsam has a markedly friendlier side-effect profile (less weight gain, sexual dysfunction, sedation, and orthostasis) and, at a steady 6 mg, no diet. But the oral agents have the real efficacy data in atypical and treatment-resistant depression, and they can be pushed to fully therapeutic doses. For a diet-averse or side-effect-sensitive patient, Emsam wins on tolerability; for true TRD, the orals win on evidence and dosing headroom.
vs. Oral Selegiline (Eldepryl)
The patch is more efficient (6 mg patch ≈ 20 mg oral) and, more to the point, keeps dietary freedom at its therapeutic dose, whereas oral selegiline must reach 30–60 mg (non-selective, diet-requiring) to treat depression. For depression, the patch has made oral selegiline all but obsolete.
vs. SSRIs/SNRIs
No head-to-head data; efficacy appears broadly similar. MAOIs as a class cause more orthostasis but fewer GI effects; the 6 mg patch specifically causes far less sexual dysfunction and weight gain than SSRIs/SNRIs. The price of the MAOI is vigilance about interactions and, at the higher patch doses, about diet.
vs. Tricyclics
Oral MAOIs may outperform TCAs specifically in atypical depression.
Limitations of Emsam
- No comparative efficacy data: everything is vs. placebo.
- No data in the populations (atypical, TRD) where MAOIs are most valuable.
- Cost: brand-only and expensive.
What Emsam Uniquely Delivers
It is the only MAOI you can prescribe without a dietary restriction (at 6 mg). Its tolerability profile is close to placebo, its visible, once-daily dosing form aids adherence, and it is a real on-ramp for the many patients (and clinicians) whose "MAOI phobia" has kept an effective drug class off the table.
Mechanism
Selegiline irreversibly inhibits monoamine oxidase, the enzyme that degrades monoamine neurotransmitters. Blocking MAO raises synaptic monoamine availability, which is the antidepressant effect.
- MAO-A metabolizes serotonin, norepinephrine, and (with MAO-B) dopamine, and it is the enzyme chiefly responsible for clearing dietary tyramine in the gut wall.
- MAO-B metabolizes dopamine.
Its selectivity is dose-dependent. At low oral doses (≤10 mg/day) selegiline is MAO-B selective (the Parkinson's use), and because it is MAO-B selective there, it doesn't require a diet. At antidepressant exposures it becomes non-selective, inhibiting MAO-A as well, which is what makes it an effective antidepressant and what, in principle, reintroduces tyramine risk.
The patch's trick is anatomical. Transdermal delivery bypasses the gut and first-pass hepatic metabolism, so at 6 mg it achieves the high central MAO-A/B inhibition needed for antidepressant effect while leaving intestinal (gut-wall) MAO-A largely intact. That preserved gut MAO-A continues to break down ingested tyramine before it can reach the circulation, so dietary tyramine can't trigger a pressor response. Push the dose to 9–12 mg and enough gut MAO becomes inhibited that the tyramine safety margin erodes, which is why the diet returns at the higher patches.
The Bedside Cheat Sheet
The master rule
- 6 mg = no diet (but keep it for 2 weeks after a reduction from 9 or 12 mg). 9 & 12 mg = Table 5 diet.
- Serotonergic and sympathomimetic rules apply at ALL doses: only the tyramine diet is dose-dependent.
Starting
- Emsam 6 mg/24 h patch, once daily; rotate site daily. 6 mg is start and usual maintenance.
- Titrate no faster than q2 weeks in 3 mg steps to a max of 12 mg/24 h, guided by orthostasis.
- 6 mg patch ≈ 20 mg oral selegiline.
Before the first patch
- Baseline seated/standing BP + HR; full med reconciliation.
- Washout: ≥2 weeks off prior antidepressant (5 weeks for fluoxetine); bridge with a benzo.
Monitoring
- No routine labs, levels, or ECG. Check BP each visit; teach home sitting-to-standing checks.
- Re-screen the med list at every visit and any time another prescriber is involved.
Side effects
- Skin irritation → rotate site, topical hydrocortisone (dry before applying).
- Orthostasis → slow titration, fluids, stockings, dose reduction; fludrocortisone if severe.
- Minimal weight gain, sexual dysfunction, and fatigue vs. older MAOIs.
Never combine (serotonin syndrome / crisis)
- SSRIs, SNRIs, clomipramine, meperidine, tramadol, dextromethorphan, St. John's wort, L-tryptophan, ziprasidone; decongestants (pseudoephedrine/phenylephrine); cocaine/amphetamines/MDMA.
- Carbamazepine is contraindicated; triptans and buspirone only with caution.
Emergencies
- Hypertensive crisis: severe "splitting" headache → check BP, get evaluated. Benzodiazepine + BP monitoring first; no nifedipine to carry; any IV drug (e.g. a phentolamine infusion) is an ED decision.
- Serotonin syndrome: clonus/hyperreflexia/hyperthermia/agitation → ED, benzodiazepines, cyproheptadine.
Stopping
- Step down, do not stop abruptly; keep diet/drug restrictions 2 weeks after the last patch (irreversible enzyme inhibition).
- No new serotonergic antidepressant until that window passes.
You don't have to become an MAOI expert overnight to use selegiline. You have to learn one threshold and one short list. At 6 mg, under the dietary line, you get an antidepressant whose common complaints are the patch site and some insomnia, and none of the dietary theater that scared a generation of prescribers away from an effective drug class. Above it, you are running a full MAOI and all the classic rules come back. At every dose, keep the serotonergic and sympathomimetic cautions in mind, run the washouts, hand the patient a one-page sheet, and re-check the medication list every visit. Emsam is the MAOI you can actually reach for, and it brings an underused mechanism to the patients most likely to have run out of easier options.